Overview

Our AFP SPEAR T-cell is aimed at the treatment of patients with hepatocellular carcinoma (HCC). A Phase I study is now open for enrollment in the United States.

Pipeline

Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
AFP TCR Hepatocellular Cancer Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Cohort 1: IND open
Research Phase complete
Pre-IND Phase in progress
Phase 1/2 Phase not started